Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Clearmind Medicine Inc. - Common Shares (NQ:CMND)

0.8800 -0.5500 (-38.46%)
Streaming Delayed Price Updated: 12:14 PM EDT, Apr 14, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Clearmind Medicine Inc. - Common Shares

< Previous 1 2 3 4 5 6 7 8 9
...
13 14 Next >
News headline image
Clearmind Medicine Obtains Clearance for its Psychedelic- Based Alcoholism Clinical Trial
From Clearmind Medicine Inc.
Via GlobeNewswire
News headline image
Clearmind Medicine Received Approval for a Voluntary Delisting of its Common Shares From the Canadian Securities Exchange
From Clearmind Medicine Inc.
Via GlobeNewswire
News headline image
Podcast: Clearmind's Non-Hallucinogenic Psychoactive Molecule Could Become A Solution For Addictive Behaviors ↗
 
Via Benzinga
News headline image
Psyched: New Evidence Shows Psilocybin As Anxiety Therapy, Open-Source Learning For Therapists, Enveric's Licensing Deals And More ↗
 
Via Benzinga
News headline image
SciSparc-Clearmind Partnership Yields Three New International Patent Applications for MDMA, Ibogaine and Ketamine Compounds
From SciSparc Ltd
Via GlobeNewswire
News headline image
Clearmind Medicine Submits Three Additional International Patent Applications for Innovative MDMA, Ibogaine and Ketamine Compounds
From Clearmind Medicine Inc.
Via GlobeNewswire
News headline image
EXCLUSIVE: Psychedelic-Focused Firm Clearmind Medicine Submits Three New International Patent Applications For MDMA, Ibogaine And Ketamine Compounds ↗
Patent applications by Clearmind Medicine for novel compositions in collaboration with SciSparc. Clearmind's CEO, highlights the significant expansion of IP protection. 
Via Benzinga
Topics Intellectual Property
News headline image
Clearmind Medicine Receives Approval to Commence its Phase I/IIa Clinical Trial of CMND-100 for Alcohol Use Disorder
From Clearmind Medicine Inc.
Via GlobeNewswire
News headline image
Next-Gen Psychedelics Companies SciSparc And Clearmind Collaboration File 3 Patents ↗
SciSparc & Clearmind file patents for LSD, psilocybin, DMT blends, advancing psychedelic therapeutics for mental health. 
Via Benzinga
Topics Intellectual Property
News headline image
What's Going On With Psychedelic Drug-Developers SciSparc And Clearmind Stock? ↗
SciSparc Ltd. and Clearmind Medicine Inc. shares are trading higher Tuesday after the companies announced the submission of three international patent applications as part of the ongoing collaboration... 
Via Benzinga
Topics Intellectual Property
News headline image
Clearmind Medicine Submits Three International Patent Applications for Next Generation Classic Psychedelic-Based Compounds
From Clearmind Medicine Inc.
Via GlobeNewswire
News headline image
SciSparc and Clearmind Continue to Strengthen International Patent Portfolio with Next Generation Classic Psychedelic-Based Compounds
From SciSparc Ltd
Via GlobeNewswire
News headline image
Psychedelics Headlines: Trauma-Informed Care, Valentine's Day & MDMA, Academics On Drugs And More ↗
 
Via Benzinga
News headline image
Psyched: Psychedelics & Sex, MDMA And Federal Approval, Canadians For End-Of-Life Care And More ↗
 
Via Benzinga
News headline image
Clearmind Medicine Receives Patent Approval for its Psychedelic Based Treatment of Binge Behaviors in China
From Clearmind Medicine Inc.
Via GlobeNewswire
News headline image
Clearmind Medicine Announces Exclusive, Long-Term Licensing Agreement with Leading Israeli Research Center
From Clearmind Medicine Inc.
Via GlobeNewswire
News headline image
Psyched: Suggestibility And Psychedelics' Effects, EU's $7M Research Fund, Australia's Treatment Delivery, BZ Podcast And More ↗
New study finds suggestibility plays a role in antidepressant effects of psilocybin therapy. EU invests 6.5M euros in psychedelics for pulmonary disorder, MS, ALS, and Parkinson's. Australian... 
Via Benzinga
News headline image
Why C.H. Robinson Shares Are Trading Lower By Over 12%? Here Are Other Stocks Moving In Thursday's Mid-Day Session ↗
Shares of C.H. Robinson Worldwide, Inc. (NASDAQ: CHRW) fell sharply during Thursday’s session after the company reported worse-than-expected fourth-quarter financial results. 
Via Benzinga
News headline image
Psychedelics Headlines: Anti-inflammatory Effects, Global Drug Survey, 'Synthetic Surprise,' UK's Harm Reduction Hub And More ↗
Discover the latest research on psychedelics, from anti-inflammatory effects to end-of-life therapy. New journal issue and online course available. 
Via Benzinga
News headline image
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday ↗
Pre-market stock movers are worth checking out on Friday as we get into all of the biggest news affecting shares this morning! 
Via InvestorPlace
News headline image
Why Humana Shares Are Trading Lower By Over 11%? Here Are Other Stocks Moving In Thursday's Mid-Day Session ↗
Shares of Humana Inc. (NYSE: HUM) fell sharply during Thursday’s session after the company reported fourth-quarter FY23 earnings and issued 2024 guidance. 
Via Benzinga
PsychedelicNewsBreaks – Clearmind Medicine Inc. (NASDAQ: CMND) (CSE: CMND) (FSE: CWY0) Selects Aegis Capital Corp. as Sole Bookrunner for $2.4M Private Placement
Via Investor Brand Network
News headline image
Clearmind Medicine Inc. Closes US$2.4 Million Registered Direct and Private Placement
From Clearmind Medicine Inc.
Via GlobeNewswire
News headline image
Aegis Capital Corp. Acted as Sole Bookrunner on a $2.4 Million Registered Direct and Private Placement for Clearmind Medicine Inc. (NASDAQ: CMND)
Via ACCESSWIRE
News headline image
Psychedelics Headlines: MDMA & Coping Skills In PTSD, LSD's Perceived Risks, Knowledge Gaps, Surveys & More ↗
Welcome to Benzinga's weekly psychedelics headlines roundup. This is our pick of must-read news items from the second week of January 2024.  
Via Benzinga
News headline image
Psyched: $100M For MDMA Therapy, VA Funds, 2024 Watchlist, Reform Updates And More ↗
Psychedelics Developer Secures $100M In Series A Funding, Will Support MDMA Approval To Treat PTSD 
Via Benzinga
News headline image
Crude Oil Moves Higher; Clearmind Medicine Shares Plummet ↗
U.S. stocks traded slightly lower toward the end of trading, with the Dow Jones index falling around 20 points on Thursday. The Dow traded down 0.05% to 37,675 while the NASDAQ fell 0.05% to 14,962.80.... 
Via Benzinga
Topics Stocks
News headline image
Why TechTarget Shares Are Trading Higher By Over 14%? Here Are Other Stocks Moving In Thursday's Mid-Day Session ↗
Shares of TechTarget, Inc. (NASDAQ: TTGT) rose sharply during Thursday’s session after the company announced a strategic combination with Informa Tech's digital businesses. TechTarget shares surged... 
Via Benzinga
News headline image
Dow Dips Over 200 Points; First Financial Northwest Shares Spike Higher ↗
U.S. stocks traded lower midway through trading, with the Dow Jones index falling over 200 points on Thursday. The Dow traded down 0.56% to 37,483.91 while the NASDAQ fell 0.86% to 14,840.28. The S&P... 
Via Benzinga
Topics Stocks
News headline image
Why Clearmind Medicine (CMND) Shares Are Nosediving ↗
Clearmind Medicine Inc (NASDAQ: CMND) shares are trading lower by 45% to $1.61 Thursday morning after the company finalized agreements with institutional investors for a 
Via Benzinga
< Previous 1 2 3 4 5 6 7 8 9
...
13 14 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.